This article is more than 5 years old. Information may no longer be current.

Clearside announces patent allowance for microneedle drug delivery

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Clearside Biomedical announced that the U.S. Patent and Trademark Office granted U.S. Patent Application No. 13/453,407 as U.S. Patent No. 8,636,713 in the patent titled “Methods and devices for drug delivery to ocular tissue using microneedle.” This is Clearside’s third patent allowance in the U.S. related to the microneedle drug delivery methods and devices.

The patent, exclusively licensed to Clearside through May 2,  2027, deals with a method of administering an anti-inflammatory drug to a patient’s eye by inserting a hollow microneedle and infusing the drug into the suprachoroidal space.

Clearside Biomedical, headquartered in Alpharetta, Ga., is a clinical-stage ophthalmic pharmaceutical company that develops and commercializes targeted therapies to treat sight-threatening diseases.